---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-063987"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T12:14:40.792418+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences Q1 net loss $72M; cash $245.7M; SUMMIT readout in July

## Summary
- Net loss $72.0M vs $58.3M YoY; R&D spend $63.0M (+20% YoY) driven by ongoing trials.
- Cash & securities $245.7M, funded into late 2026; raised $24.3M via ATM in Q1.
- Top-line SUMMIT results in non-AdvSM due July 2025; APEX AdvSM in H2, PEAK GIST by year-end.
- Bezuclastinib OLE data showed 65% mean TSS improvement at 48 weeks; 88% achieved ≥50% reduction.
- Early-stage pipeline (KRAS, PI3Kα, FGFR2/3, ErbB2) preclinical data presented at AACR.

## SEC filing metadata
- accession: 0000950170-25-063987
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000095017025063987/0000950170-25-063987-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000095017025063987/cogt-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-063987
- JSON: https://secwatch.observer/filing/0000950170-25-063987.json
- Plain text: https://secwatch.observer/filing/0000950170-25-063987.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.